Table 1 Transitional Probabilities per Development Phase from 1993–2004
From: Incentives for new antibiotics: the Options Market for Antibiotics (OMA) model
Therapeutic class | Phase I-II (%) | Phase II-III (%) | Phase III- RR (%) | RR-approval (%) | Clinical approval success rate (%) |
|---|---|---|---|---|---|
Anitneoplastic/immunologic | 71.8 | 49.0 | 55.3 | 100 | 19.4 |
Cardiovascular | 62.9 | 32.4 | 64.3 | 66.7 | 8.7 |
CNS | 59.6 | 33.0 | 46.4 | 90.0 | 8.2 |
GI/metabolism | 67.5 | 34.9 | 50.0 | 80.0 | 9.4 |
Musculoskeletal | 72.4 | 35.2 | 80.0 | 100 | 20.4 |
Respiratory | 72.5 | 20.0 | 85.7 | 80.0 | 9.9 |
Systemic anti-infective | 58.2 | 52.2 | 78.6 | 100 | 23.9 |
Miscellaneous | 62.8 | 48.7 | 69.8 | 91.3 | 19.5 |